2. Treatment groups in included trials.

Study Treatment period	Intervention 1	Intervention 2	Intervention 3	Intervention 4
Pegaptanib vs control
VISION 2004 2 years; re‐randomized at end of first year	0.3 mg pegaptanib every 6 weeks	1.0 mg pegaptanib every 6 weeks	3.0 mg pegaptanib every 6 weeks	Sham every 6 weeks
Ranibizumab vs control
ANCHOR 2006 2 years	0.3 mg ranibizumab monthly plus sham verteporfin PDT	0.5 mg ranibizumab monthly plus sham verteporfin PDT	Sham intravitreal injection plus verteporfin PDT	‐
MARINA 2006 2 years	0.3 mg ranibizumab monthly	0.5 mg ranibizumab monthly	Sham intravitreal injection monthly	‐
PIER 2008 2 years	0.3 mg ranibizumab monthly for 3 months, then every 3 months	0.5 mg ranibizumab monthly for 3 months, then every 3 months	Sham intravitreal injection monthly for 3 months, then every 3 months	‐
Bevacizumab vs control
ABC 2010 1 year	1.25 mg bevacizumab given first 3 injections every 6 weeks, then as needed	Standard therapy (0.3 mg pegaptanib every 6 weeks, verteporfin PDT, or sham injection)	‐	‐
Sacu 2009 1 year	1.0 mg bevacizumab monthly for 3 months, then as needed	Verteporfin PDT plus same day 4 mg triamcinolone acetonide	‐	‐
Bevacizumab vs ranibizumab
CATT 2011 2 years; re‐randomized at end of first year	1.25 mg bevacizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing	0.5 mg ranibizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing	1.25 mg bevacizumab as needed after first injection for 2 years	0.5 mg ranibizumab as needed after first injection for 2 years
IVAN 2013 2 years; ongoing	1.25 mg bevacizumab monthly for 2 years	0.5 mg ranibizumab monthly for 2 years	1.25 mg bevacizumab monthly for 3 months, then as needed in 3‐month cycles	0.5 mg ranibizumab monthly for 3 months, then as needed in 3‐month cycles
Biswas 2011 18 months	1.25 mg bevacizumab monthly for 3 months, then as needed	0.5 mg ranibizumab monthly for 3 months, then as needed	‐	‐
BRAMD 2016 1 year	1.25 mg bevacizumab monthly for 1 year	0.5 mg ranibizumab monthly for 1 year	‐	‐
GEFAL 2013 1 year	1.25 mg bevacizumab; maximum of 1 injection per month	0.5 mg ranibizumab; maximum of 1 injection per month	‐	‐
LUCAS 2015 1 year	1.25 mg bevacizumab; treat and extend protocol	0.5 mg ranibizumab; treat and extend protocol	‐	‐
MANTA 2013 1 year	1.25 mg bevacizumab monthly for 3 months, then as needed	0.5 mg ranibizumab monthly for 3 months, then as needed	‐	‐
SAVE‐AMD 2017 1 year	1.25 mg bevacizumab at day 1 and at week 4, then as needed	0.5 mg ranibizumab at day 1 and at week 4, then as needed	‐	‐
Scholler 2014 1 year	1.25 mg bevacizumab for 3 months, at 30‐day intervals, then as needed	0.5 mg ranibizumab for 3 months, at 30‐day intervals, then as needed	‐	‐
Subramanian 2010 1 year	0.05 mL bevacizumab monthly for 3 months, then as needed	0.05 mL ranibizumab monthly for 3 months, then as needed	‐	‐

PDT: photodynamic therapy.